Fundz

Chiesi Group to acquire KalVista Pharmaceuticals

PRIVATEMay 08, 2026

Acquiring Company

Chiesi Group

Acquired Company

KalVista Pharmaceuticals

ParmaCambridgeBiotechnologyHealth CareMedicalBiotechnologyHealth Careresearch

Description

Chiesi Group has announced its agreement to acquire KalVista Pharmaceuticals for $27.00 per share in cash, totaling approximately $1.9 billion. This acquisition strengthens Chiesi's portfolio in rare diseases, particularly with the addition of sebetralstat for treating hereditary angioedema. The transaction is expected to close in Q3 2026, following customary closing conditions. This move aligns with Chiesi's strategic goals to enhance patient access to crucial therapies.

Quick answer

Chiesi Group is acquiring KalVista Pharmaceuticals, announced May 8, 2026. Chiesi Group is based in Parma, Emilia-Romagna, Italy.

How much did Chiesi Group pay for KalVista Pharmaceuticals?
The deal value was not disclosed.
What does Chiesi Group do?
Chiesi Group is a research-oriented international biopharmaceutical group dedicated to improving patients' lives.
Where are Chiesi Group and KalVista Pharmaceuticals based?
Chiesi Group is based in Parma, Emilia-Romagna, Italy. KalVista Pharmaceuticals is based in Cambridge, Massachusetts, United States.
Who are the decision-makers at Chiesi Group?
Fundz holds 5 contacts at Chiesi Group. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who to call at Chiesi Group, and when

When Chiesi Group changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day Chiesi Group raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Chiesi Group, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Chiesi Group. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Chiesi Group

Location

Parma, Emilia-Romagna, Italy

About

Chiesi Group is a research-oriented international biopharmaceutical group dedicated to improving patients' lives. With a focus on innovative healthcare solutions, Chiesi aims to tackle challenges in healthcare by addressing both symptoms and root causes. The company fosters collaboration among researchers, startups, and innovators to drive advancements in patient care. Chiesi is committed to sustainable healthcare practices that consider the impacts of climate change.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Chiesi Group makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Yves
Likely contact at this company
••••••••@••••••••

See Yves's verified email →

Lisa
Likely contact at this company
••••••••@••••••••

See Lisa's verified email →

Alessandro
Likely contact at this company
••••••••@••••••••

See Alessandro's verified email →

Fabrizio
Senior decision-maker at this company
••••••••@••••••••

See Fabrizio's verified email →

Stefano
Senior decision-maker at this company
••••••••@••••••••

See Stefano's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Chiesi Group's next move

Learn about Strategic plan

Frequently asked

Who acquired KalVista Pharmaceuticals?

KalVista Pharmaceuticals was acquired by Chiesi Group, based in Parma. The deal was reported on May 8, 2026. Chiesi Group is a research-oriented international biopharmaceutical group dedicated to improving patients' lives. Chiesi Group is privately held and operates in Biotechnology.

When did Chiesi Group acquire KalVista Pharmaceuticals?

Chiesi Group's acquisition of KalVista Pharmaceuticals was reported on May 8, 2026. Chiesi Group has announced its agreement to acquire KalVista Pharmaceuticals for $27.00 per share in cash, totaling approximately $1.9 billion. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does KalVista Pharmaceuticals do?

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. It is privately held, operating in Biotechnology, and is based in Cambridge.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.